Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price objective hoisted by Morgan Stanley from $359.00 to $364.00 in a research report report published on Wednesday morning, Benzinga reports. They currently have an equal weight rating on the pharmaceutical company’s stock. VRTX has been the topic of a number of other reports. Wells Fargo & […]